Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 1/20 | 0.84 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.69 |
| ▸ | DHODH | Q02127 | 1/20 | 0.67 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.60 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472419 | 1.00 | LTC4S (0.84) | LTC4SSERPINE1DHODHIGF2BP2PDCD1 | |
| SCHEMBL14413321 | 0.93 | LTC4S (0.72) | LTC4SSERPINE1DHODHIGF2BP2PDCD1 | |
| SCHEMBL14075422 | 0.91 | LTC4S (1.00) | LTC4SSERPINE1DHODHMAPTPKM | |
| SCHEMBL14075191 | 0.91 | LTC4S (0.69) | LTC4SSERPINE1DHODHIGF2BP2PDCD1 | |
| SCHEMBL14413323 | 0.89 | LTC4S (0.67) | LTC4SSERPINE1DHODHIGF2BP2NPC1 | |
| SCHEMBL14413319 | 0.86 | LTC4S (0.65) | LTC4SSERPINE1NPC1RAB9AMAPT | |
| SCHEMBL6353351 | 0.82 | SERPINE1 (0.71) | LTC4SSERPINE1DHODHIGF2BP2PDCD1 | |
| SCHEMBL421010 | 0.82 | SERPINE1 (1.00) | SERPINE1DHODHIGF2BP2MEN1KMT2A | |
| SCHEMBL14075221 | 0.82 | MEN1 (0.72) | SERPINE1DHODHIGF2BP2NPC1RAB9A | |
| SCHEMBL1954779 | 0.81 | MEN1 (0.72) | LTC4SSERPINE1DHODHIGF2BP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429677-B2 | Small molecule entry inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-09-30 | — | — | US | disclosed |
| US-7429677-B2 | Small molecule entry inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-09-30 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | AMBION, INC (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | AMBION, INC (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | RNASE1, RNASEH1, RNASEL | LTC4S 2560/4885SERPINE1 5/4885DHODH 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.